Interim analysis of Phase III monarchE study of abemaciclib combined with standard adjuvant endocrine therapy in patients with high risk, node positive, HR+, HER2- early breast cancer meets primary endpoint

The monarchE study (n=5637) of this CDK4 & 6 inhibitor plus standard adjuvant endocrine therapy (SAET) vs. SAET alone met its primary endpoint of invasive disease-free survival. Data are to be submitted to regulatory authorities before end of 2020.

Source:

Biospace Inc.